Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma

@article{Yoshikawa2009VandetanibA,
  title={Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma},
  author={Daitaro Yoshikawa and Hidenori Ojima and Ayaka Kokubu and Takahiro Ochiya and Syuya Kasai and Setsuo Hirohashi and Tatsuhiro Shibata},
  journal={British Journal of Cancer},
  year={2009},
  volume={100},
  pages={1257 - 1266}
}
Cholangiocarcinoma is an intractable cancer, with no effective therapy other than surgical resection. Elevated vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) expressions are associated with the progression of cholangiocarcinoma. We therefore examined whether inhibition of VEGFR and EGFR could be a potential therapeutic target for cholangiocarcinoma. Vandetanib (ZD6474, ZACTIMA), a VEGFR-2/EGFR inhibitor, was evaluated. Four human cholangiocarcinoma cell… CONTINUE READING